dasatinib
Showing 1 - 25 of 229
Acute Myeloid Leukemia Trial (Dasatinib)
Not yet recruiting
- Acute Myeloid Leukemia
- Dasatinib
- (no location specified)
Sep 20, 2023
Lymphoblastic Leukemia Trial in Palo Alto (Dasatinib)
Not yet recruiting
- Lymphoblastic Leukemia
- Dasatinib
-
Palo Alto, CaliforniaStanford University
Aug 14, 2023
Solid Tumors Trial run by the National Cancer Institute (NCI) (Bevacizumab, Dasatinib)
Completed
- Solid Tumors
- Bevacizumab
- Dasatinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)
Completed
- Advanced Cancer
- Dasatinib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 21, 2022
Glioma, High Grade Glioma, Pontine Tumors Trial in Ann Arbor (Dasatinib, Everolimus)
Terminated
- Glioma
- +2 more
- Dasatinib
- Everolimus
-
Ann Arbor, MichiganUniversity of Michigan Cancer Center
Sep 26, 2022
Advanced Cancers Trial in Houston (Crizotinib, Dasatinib)
Completed
- Advanced Cancers
- Crizotinib
- Dasatinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jun 29, 2022
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +4 more
- Dasatinib
- +5 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 20, 2023
Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia
- +3 more
- Dasatinib
- Decitabine and Cedazuridine
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Dasatinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 24, 2022
Acute,Leukemia, Lymphoid Trial in Tianjin (Dasatinib, prednisone, cyclophosphamide)
Completed
- Acute,Leukemia, Lymphoid
- Dasatinib
- +12 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 2, 2022
Waldenstrom Macroglobulinemia, DASATINIB Trial in Boston (Dasatinib)
Recruiting
- Waldenstrom Macroglobulinemia
- DASATINIB
- Dasatinib
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 22, 2022
Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)
Recruiting
- Chronic Myeloid Leukemia in Chronic Phase
- Flumatinib
- Dasatinib
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Jul 26, 2022
Acute Lymphoblastic Leukemia Trial in New York (Ruxolitinib, Dasatinib, Dexamethasone)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- Ruxolitinib
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 25, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Breast Tumors, Triple Negative Breast Tumors Trial in Chicago, Madison (drug, procedure, other)
Terminated
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Dasatinib
- +2 more
-
Chicago, Illinois
- +1 more
Jun 2, 2022
Prostate Cancer Trial (Dasatinib)
Withdrawn
- Prostate Cancer
- Dasatinib
- (no location specified)
Feb 23, 2022
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Trial in Valencia (dasatinib)
Completed
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- dasatinib
-
Valencia, SpainHospital La Fe
Mar 16, 2022
Malignant Pleural Mesothelioma Trial in Houston (Dasatinib)
Active, not recruiting
- Malignant Pleural Mesothelioma
- Dasatinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 25, 2022
Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)
Terminated
- Rhabdomyosarcoma
- +2 more
- Dasatinib
- Ganitumab
-
Los Angeles, California
- +1 more
Mar 17, 2022
Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic Trial in Guangzhou (Chidamide, Dasatinib)
Recruiting
- Leukemia
- +3 more
- Chidamide
- Dasatinib
-
Guangzhou, Guangdong, ChinaDepartment of Hematology, Nanfang Hospital
Jun 28, 2022
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 Trial in
Active, not recruiting
- Metastatic Pancreatic Adenocarcinoma
- +3 more
- Dasatinib
- +2 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Dec 15, 2021
Multiple Indications Cancer Trial in France, Poland (Dasatinib)
Active, not recruiting
- Multiple Indications Cancer
- Dasatinib
-
Besancon, France
- +5 more
Dec 2, 2021
Breast Cancer, Bone Metastases Trial in Chicago, Durham, Houston (Dasatinib, Zoledronic Acid)
Completed
- Breast Cancer
- Bone Metastases
- Dasatinib
- Zoledronic Acid
-
Chicago, Illinois
- +2 more
Feb 2, 2022
Mild Cognitive Impairment, Alzheimer Trial in Rochester (Dasatinib, Quercetin)
Enrolling by invitation
- Mild Cognitive Impairment
- Alzheimer Disease
- Dasatinib
- Quercetin
-
Rochester, MinnesotaMayo Clinic in Rochester
Jul 2, 2022